EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

Arexvy by GlaxoSmithKline Biologicals S.A. has been authorised for use in the European Union for Respiratory Syncytial Virus infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Arexvy

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 18/08/2026